CI-988 is a selective and effective antagonist of CCK-BR (CCK2; CCK-B; cholecystokinin 2) receptors. CCK is a neuroendocrine peptide described to play an important role in cell growth, cell proliferation, and other biological functions. Lung cancer cell studies report that Cl 988 inhibits the proliferation of NCI-H209 cells in vitro and the binding of CCK-8 to NCI-H209 cells. In addition Cl 988 blocks the elevated levels of cytosolic Ca2+ induced by CCK-8. Other CCK-BR inhibitors include L-365,260 (sc-205244).
1. Hughes, J., et al. 1990. Proc. Natl. Acad. Sci. U.S.A. 87: 6728-6732. PMID: 1975695
2. Coudoré-Civiale, M.A., et al. 2000. Pain. 88: 15-22. PMID: 11098095
3. Moody, T.W., et al.2001. J. Pharmacol. Exp. Ther. 299: 1154-1160. PMID: 11714907
4. Carrillo, J.., et al. 2009. Anticancer Drugs. 20: 527-533. PMID: 19407653
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.